Argus Research analyst John Staszak downgrades Wolverine World Wide (NYSE:WWW) from Buy to Hold.
Merck’s Two Keytruda Combo Cancer Trials Miss Primary Goal
Merck & Co Inc’s (NYSE:MRK) Phase 3 KEYNOTE-921 trial of Keytruda combined with chemotherapy (docetaxel) did not meet its dual…